SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis First Subcutaneous Anti-TNF to Launch ...

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of ...

rheumatoid arthritis and ankylosing spondylitis in adults psoriatic arthritis in adults and children ages 2 years and older polyarticular juvenile idiopathic arthritis in children ages 2 years and ...

What Is Simponi, and Why Does It Matter? The FDA has approved Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kilograms (33 pounds).

If you have a certain kind of autoimmune condition, your doctor might suggest Simponi or Simponi Aria as a treatment option for you. The active ingredient in Simponi and Simponi Aria is golimumab. An ...